Clinical Trial

at the Medical University of Graz

read more

Tremipen: the innovative mobile measurement device for Parkinson’s and tremor patients

Klagenfurt, March 2018 – The Tremipen is the first mobile medical product for tremor assessment that can be used by the patient every time and…

some image

For a measurement the small device, that extracts parameters for tremor force and frequency in just 30 seconds, is held like a regular pen in one hand. With the results, that can be noted in a diary, patients can better overlook their disease, changes are perceived more quickly and the communication with the doctor is more efficient. The  Tremipen collects objective data, that can support in diagnosis and choice of therapy. After many promising tests and a clinical trial at the Medical University of Graz, the young med-tech start-up can approach the medical certification. In line with the World Parkinson’s Day the crowdfunding campaign starts at 11th of April at Indiegogo ( with a duration of 30 days.

With the campaign’s start patients and interested people can pre-order the Tremipen or support the project financially. “We have set ourselves the goal to reach the 30.000 Euros threshold within the 30 days duration. This amount of money helps us to complete the certification process and bring the Tremipen to the market”, says Tibor Zajki-Zechmeister, founder of Tremitas.

The delivery of the product is planned for this July. „We would be happy to reach the target as soon as possible. But we have more in mind”, says Zajki-Zechmeister. With reaching the next goal of 50.000 Euros, additions for the product, like an app, are planned. Via smartphone or notebook, the measurement results can be saved and visualised. Open interfaces of the system will make integration into telemedical connection possible.

Since 2011 the start-up’s founder Tibor Zajki-Zechmeister is working on the idea to help tremor and Parkinson’s patients. Since 2013 he was working very intensively on the development of the Tremipen and often gets positive feedback. For example from Markus N., a patient with Parkinson’s Disease, who had the opportunity to test the Tremipen: “I can better understand the shaking and learn what helps and what increases it. Due to the objective measurements I have more certainty.”

The pen is also convincing in comparison to other available tools. That was also confirmed by some doctors to Tremitas. Ass. Mariella Kögl, doctor at the neurogeriatric department in Graz, says: „The internationally acknowledged method for tremor quantification is the EMG Accelerometry but it is time consuming, bound to clinics and needs special know how. Alternatives like smartphone apps are available but these are not CE certified and therefore not scientifically validated. In our opinion the Tremipen® is a mobile, easy to use and therefore a promising tool for tremor assessment.“

Not at last it had been supporters that encouraged Tremitas to finalise the development. Among others, the Österreichische Forschungsförderungsgesellschaft FFG, supported Tremitas. The FFG is the most important institution for companies that committed to research and development.